Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review
Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease
Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).
5 findings from 1 review
RR 1.04 [0.79, 1.36]
3 studies · 178 participants
Moderate
RR 0.95 [0.49, 1.85]
1 study · 50 participants
Low
RR 1 [0.61, 1.64]
1 study · 50 participants
Moderate
Show 2 more findings
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).
2 findings from 1 review
Induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2 g/day) · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency or change in pain frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
At least 30% reduction in pain · people with Crohn's disease
It is very uncertain whether 100 mg olorinab 3 times/day changes pain intensity (30% reduction in weekly AAPS) compared with 25 mg olorinab 3 times/day (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in H. pylori persistence, PAN subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PAQ subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PANi subgroup · patients with Helicobacter pylori infection
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PANi subgroup compared with 7 days (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, regardless of regimen and dose compared with 10 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, PCA subgroup compared with 10 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in H.pylori persistence, PAN subgroup compared with 10 days (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in H. pylori persistence, PCN subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PAN subgroup compared with 7 days (moderate certainty).
1 finding from 1 review